Christopher H. Crane
#160,989
Most Influential Person Now
Christopher H. Crane's AcademicInfluence.com Rankings
Christopher H. Cranemedical Degrees
Medical
#3238
World Rank
#3696
Historical Rank
Oncology
#224
World Rank
#232
Historical Rank
Surgery
#277
World Rank
#337
Historical Rank
Christopher H. Cranephilosophy Degrees
Philosophy
#9283
World Rank
#12820
Historical Rank
Logic
#6267
World Rank
#7770
Historical Rank
Download Badge
Medical Philosophy
Christopher H. Crane's Degrees
- Doctorate Medicine Harvard University
- PhD Biomedical Sciences Harvard University
Why Is Christopher H. Crane Influential?
(Suggest an Edit or Addition)Christopher H. Crane's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy (2006) (762)
- Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. (2008) (730)
- Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. (2008) (699)
- Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. (2011) (670)
- Pancreaticoduodenectomy with vascular resection: margin status and survival duration (2004) (545)
- Impact of Resection Status on Pattern of Failure and Survival After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma (2007) (538)
- Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma (2009) (449)
- Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators (2012) (444)
- Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. (2008) (444)
- Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. (2012) (411)
- Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. (2006) (341)
- Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications (2014) (336)
- Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival Duration (2001) (336)
- Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (2018) (328)
- Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. (2016) (318)
- Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer (2007) (307)
- Hilar cholangiocarcinoma: expert consensus statement. (2015) (280)
- Improved Overall Survival Among Responders to Preoperative Chemoradiation for Locally Advanced Rectal Cancer (2001) (280)
- Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy (2019) (273)
- Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2016) (273)
- Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy (2007) (270)
- Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. (2011) (263)
- Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. (2005) (262)
- Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2016) (241)
- Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. (2016) (239)
- Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. (2019) (231)
- Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? (2001) (213)
- Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. (2006) (207)
- Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma (2012) (204)
- Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. (2016) (197)
- Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. (2001) (189)
- Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. (2010) (189)
- Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. (2018) (187)
- Response to preoperative chemoradiation increases the use of sphincter‐preserving surgery in patients with locally advanced low rectal carcinoma (2003) (185)
- Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival (2013) (174)
- Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. (2007) (168)
- Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy. (2017) (167)
- Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes (2013) (166)
- Clinical and Pathologic Predictors of Locoregional Recurrence, Distant Metastasis, and Overall Survival in Patients Treated With Chemoradiation and Mesorectal Excision for Rectal Cancer (2006) (159)
- A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 (2008) (158)
- Transport properties of pancreatic cancer describe gemcitabine delivery and response. (2014) (156)
- Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. (2012) (154)
- Perineural and Intraneural Invasion in Posttherapy Pancreaticoduodenectomy Specimens Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma (2012) (146)
- Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial (2017) (145)
- Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. (2014) (144)
- Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. (2006) (139)
- Pain and quality of life after treatment in patients with locally recurrent rectal cancer. (2002) (133)
- Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation (2010) (132)
- Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. (2009) (127)
- Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. (2006) (126)
- The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer. (2003) (124)
- Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience (2016) (122)
- Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? (2007) (118)
- Results of Surgical Salvage after Failed Chemoradiation Therapy for Epidermoid Carcinoma of the Anal Canal (2004) (111)
- Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. (2007) (107)
- Local Excision After Preoperative Chemoradiation Results in an Equivalent Outcome to Total Mesorectal Excision in Selected Patients with T3 Rectal Cancer (2010) (106)
- Metastatic Pancreatic Cancer: ASCO Guideline Update. (2020) (102)
- Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma. (2009) (102)
- Planned neck dissection as an adjunct to the management of patients with advanced neck disease treated with definitive radiotherapy: For some or for all? (1999) (101)
- Long‐term quality of life after radiotherapy for the treatment of anal cancer (2010) (101)
- Radiographic Tumor–Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic Cancer (2014) (101)
- Long-Term Survival and Recurrence Outcomes Following Surgery for Distal Rectal Cancer (2010) (99)
- Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer (2011) (96)
- Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients (2015) (95)
- The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal (2014) (93)
- Upper abdominal normal organ contouring guidelines and atlas: a Radiation Therapy Oncology Group consensus. (2014) (92)
- Clinical benefit of palliative radiation therapy in advanced gastric cancer (2008) (90)
- Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer (2015) (89)
- Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. (2006) (88)
- Extrahepatic Bile Duct Adenocarcinoma: Patients at High-Risk for Local Recurrence Treated with Surgery and Adjuvant Chemoradiation Have an Equivalent Overall Survival to Patients with Standard-Risk Treated with Surgery Alone (2008) (86)
- Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results (2019) (85)
- Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma (2011) (84)
- Limitations of conventional doses of chemoradiation for unresectable biliary cancer (2002) (84)
- Metformin use and improved response to therapy in rectal cancer (2013) (83)
- Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. (2011) (83)
- Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy (2012) (80)
- Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. (2002) (79)
- Radiotherapy for Hepatocellular Carcinoma: An Overview (2008) (78)
- NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer. (2015) (78)
- Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation (2006) (77)
- Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. (2000) (77)
- Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. (2019) (75)
- Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis. (2011) (75)
- Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance (2016) (74)
- Proton radiotherapy for liver tumors: dosimetric advantages over photon plans. (2008) (74)
- Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? (2017) (74)
- Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. (2005) (74)
- Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. (2008) (73)
- Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer (2001) (72)
- Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Anal Cancer: Outcomes and Toxicity (2014) (71)
- Management of borderline resectable pancreatic cancer. (2014) (70)
- Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). (2009) (70)
- Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. (1997) (70)
- Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head (2001) (70)
- Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer (2016) (65)
- The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head Adenocarcinoma (2013) (64)
- Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. (2017) (62)
- Neoadjuvant therapy for resectable pancreatic cancer. (2004) (62)
- Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. (2001) (61)
- Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. (2021) (61)
- T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment. (2001) (61)
- Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. (2000) (60)
- A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma (2018) (60)
- Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy (2006) (59)
- Chemoradiation for adenocarcinoma of the anus. (2003) (59)
- Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. (2008) (58)
- Molecular Biomarkers Correlate with Disease-Free Survival in Patients with Anal Canal Carcinoma Treated with Chemoradiation (2010) (58)
- Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. (2001) (58)
- Borderline resectable pancreatic cancer (2005) (57)
- Number of lymph nodes examined and prognosis among pathologically lymph node‐negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma (2011) (56)
- Impact of Induction Chemotherapy and Preoperative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction (2007) (56)
- Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. (2009) (56)
- Dose escalation with proton or photon radiation treatment for pancreatic cancer. (2009) (55)
- Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. (2007) (52)
- Optimal Management of Gastric Cancer: Results From an International RAND/UCLA Expert Panel (2014) (52)
- Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta‐analysis (2020) (51)
- Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. (2012) (50)
- Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence‐free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy (2013) (50)
- Limitations of conventional doses of chemoradiation for unresectable biliary cancer. (2002) (49)
- Intraoperative radiation therapy for locally advanced primary and recurrent colorectal cancer: Ten‐year institutional experience (2014) (49)
- Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer (2015) (47)
- Palliative and postoperative radiotherapy in biliary tract cancer. (2002) (46)
- Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study. (2013) (45)
- Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma (2016) (44)
- Initial Experience Combining Cyclooxygenase-2 Inhibition with Chemoradiation for Locally Advanced Pancreatic Cancer (2003) (43)
- Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. (2009) (43)
- The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. (2006) (42)
- Fatigue during preoperative chemoradiation for resectable rectal cancer (2001) (41)
- Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma (2006) (41)
- Conformal Radiotherapy of the Dominant Liver Metastasis: A Viable Strategy For Treatment of Unresectable Chemotherapy Refractory Colorectal Cancer Liver Metastases (2006) (39)
- The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy (2015) (39)
- Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality (2016) (39)
- Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme. (2003) (39)
- Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. (2017) (39)
- Evaluation of Adjuvant Radiation Therapy for Resected Gallbladder Carcinoma: A Multi-institutional Experience (2015) (38)
- Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel. (2014) (38)
- RTOG 0822: A Phase II Study of Preoperative (PREOP) Chemoradiotherapy (CRT) Utilizing IMRT in Combination with Capecitabine (C) and Oxaliplatin (O) for Patients with Locally Advanced Rectal Cancer (2011) (36)
- Recommendations for MRI-based contouring of gross tumor volume and organs at risk for radiation therapy of pancreatic cancer. (2017) (36)
- Prognostic factors for squamous cell cancer of the anal canal. (2008) (35)
- Current Approaches and Future Strategies for Pancreatic Carcinoma (2000) (34)
- RTOG 0436: A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery. (2014) (33)
- Impact of multimodal therapy in locally recurrent rectal cancer (2016) (33)
- Imaging‐based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy (2018) (32)
- Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center (2020) (32)
- Future chemoradiation strategies in pancreatic cancer. (2007) (32)
- Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010. (2020) (32)
- Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement. (2008) (31)
- Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529. (2017) (31)
- Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. (2020) (31)
- Occult carcinoma discovered after simple hysterectomy treated with postoperative radiotherapy. (1999) (31)
- Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients (2017) (30)
- Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer (2014) (30)
- The initial report of RTOG 0436: A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery. (2014) (30)
- Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer (2017) (29)
- Neoadjuvant strategies for pancreatic cancer. (2001) (29)
- Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. (2015) (28)
- Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. (2019) (28)
- Interobserver variability in target definition for hepatocellular carcinoma with and without portal vein thrombus: radiation therapy oncology group consensus guidelines. (2014) (28)
- Substitution of oral fluoropyrimidines for infusional fluorouracil with radiotherapy: how much data do we need? (2004) (28)
- Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. (2012) (28)
- Reproducibility and genital sparing with a vaginal dilator used for female anal cancer patients. (2012) (27)
- A High Positive Lymph Node Ratio is Associated with Distant Recurrence after Surgical Resection of Ampullary Carcinoma (2012) (27)
- Survival and Quality of Life of Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Interferon-Based Chemoradiation: A Phase II Trial (2011) (27)
- Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. (2020) (27)
- Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness Method. (2016) (26)
- Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer (2021) (26)
- Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer (2007) (26)
- Elective groin irradiation is not indicated for patients with adenocarcinoma of the rectum extending to the anal canal. (2001) (26)
- The role of intraoperative radiotherapy in pancreatic cancer. (2003) (26)
- Combined-modality treatment for operable pancreatic adenocarcinoma. (2005) (26)
- Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. (2018) (26)
- Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal. (2009) (25)
- Long‐term results of weekly/daily cisplatin‐based chemoradiation for locally advanced squamous cell carcinoma of the anal canal (2013) (25)
- Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments? (2017) (24)
- Cost-effectiveness of Treatment Strategies for Pancreatic Head Adenocarcinoma and Potential Opportunities for Improvement (2012) (24)
- Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer. (2009) (24)
- Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC (2017) (23)
- Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum (2012) (23)
- Outcome After Curative Resection for Locally Recurrent Rectal Cancer (2006) (22)
- Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial (2022) (22)
- Chemotherapy for pancreatic cancer. (2004) (22)
- Combined-modality therapy for gastric cancer. (2003) (21)
- Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy. (2008) (21)
- Randomized, Double-Blind, Placebo-Controlled Trial of Epoetin Alfa (Procrit) in Patients with Rectal and Gastric Cancer Undergoing Chemo-Radiotherapy (CT/RT) Followed by Surgery: Early Termination of the Trial Due to Increased Incidence of Thrombo-Embolic Events (TEE). (2004) (21)
- Surgical placement of biologic mesh spacers to displace bowel away from unresectable liver tumors followed by delivery of dose-intense radiation therapy. (2014) (21)
- Proton beam radiation as salvage therapy for bilateral colorectal liver metastases not amenable to second‐stage hepatectomy (2017) (21)
- Keys to personalized care in pancreatic oncology. (2012) (20)
- Concurrent capecitabine and upper abdominal radiation therapy is well tolerated (2006) (20)
- Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question—Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head (2020) (20)
- Feasibility of ablative stereotactic body radiation therapy of pancreas cancer patients on a 1.5 Tesla magnetic resonance-linac system using abdominal compression (2021) (20)
- Reirradiation to the abdomen for gastrointestinal malignancies (2009) (19)
- Compliance with therapeutic guidelines in Radiation Therapy Oncology Group prospective gastrointestinal clinical trials. (2012) (19)
- Phase I trial of bevacizumab (BV) with concurrent radiotherapy (RT) and capecitabine (CAP) in locally advanced pancreatic adenocarcinoma (PA) (2005) (19)
- Improving soft-tissue contrast in four-dimensional computed tomography images of liver cancer patients using a deformable image registration method. (2008) (18)
- Preoperative chemoradiation for locally advanced rectal cancer: rationale, technique, and results of treatment. (2003) (18)
- Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. (2012) (18)
- Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. (2001) (17)
- Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. (2014) (17)
- Changes in the multidisciplinary management of rectal cancer from 2009 to 2015 and associated improvements in short‐term outcomes (2019) (17)
- Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma (2018) (17)
- The Added Value of Multidisciplinary Care for Patients with Pancreatic Cancer (2008) (16)
- The integration of chemoradiation in the care of patient with localized pancreatic cancer. (2009) (16)
- Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811. (2017) (16)
- Phase II trial of neoadjuvant bevacizumab (BEV), capecitabine (CAP), and radiotherapy (XRT) for locally advanced rectal cancer (2008) (16)
- Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma (2016) (16)
- Single Nucleotide Polymorphisms of RecQ 1 , RAD 54 L and ATM Genes Are Associated With Reduced Survival of Pancreatic Cancer (2008) (16)
- RTOG 0438: A phase I trial of highly conformal radiation therapy for patients with liver metastases. (2012) (16)
- Radiation treatment outcomes for unresectable hepatocellular carcinoma (2011) (15)
- Current treatment for localized anal carcinoma (2007) (15)
- Interstitial Brachytherapy for the Treatment of Locally Recurrent Anorectal Cancer (2015) (15)
- Optimization of beam orientations and weights for coplanar conformal beams in treating pancreatic cancer. (1999) (15)
- Image-Guided Radiation Therapy Committee (2001) (15)
- WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment (2001) (14)
- Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy (2018) (14)
- Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions (2021) (14)
- Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation (2016) (14)
- Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. (2008) (14)
- Ablative Radiotherapy Doses for Locally Advanced: Pancreatic Cancer (LAPC) (2017) (13)
- Long term Outcomes of NRG Oncology/RTOG 0529: A Phase II Evaluation of Dose-Painted Intensity Modulated Radiation Therapy (DP-IMRT) in Combination with 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer. (2021) (13)
- Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers (2017) (13)
- NRG Oncology/RTOG 0529: Long-Term Outcomes of Dose-Painted Intensity Modulated Radiation Therapy, 5-Fluorouracil, and Mitomycin-C in Anal Canal Cancer (2017) (13)
- Preoperative chemoradiation for locally advanced rectal cancer: emerging treatment strategies. (2002) (13)
- Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy (2017) (13)
- Dose Reduction to Small Bowel and Other Relevant Structures in Rectal Carcinoma With Proton Therapy (2012) (13)
- Radiation Therapy Oncology Group. Research Plan 2002-2006. Image-Guided Radiation Therapy Committee. (2001) (13)
- Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy (2018) (12)
- What provider volumes and characteristics are appropriate for gastric cancer resection? Results of an international RAND/UCLA expert panel. (2013) (12)
- Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma. (2017) (12)
- Radiation Dose Considerations in the Palliative Treatment of Locally Advanced Adenocarcinoma of the Pancreas (2005) (12)
- Radiation segmentectomy of hepatic metastases with Y-90 glass microspheres (2021) (12)
- Computed Tomography–Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer (2019) (12)
- Evaluation of response after chemoradiation for rectal cancer as a predictive factor for the benefit of adjuvant chemotherapy: A pooled analysis of 2,724 individual patients. (2011) (12)
- Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal (2017) (11)
- Multidetector Computed Tomography Follow-up of Hypoattenuating Small Liver Lesions in Patients With Rectal Cancer (2011) (11)
- Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal. (2014) (11)
- Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus (2017) (11)
- Deep-learning-based image registration and automatic segmentation of organs-at-risk in cone-beam CT scans from high-dose radiation treatment of pancreatic cancer. (2021) (11)
- Consensus Report From the Miami Liver Proton Therapy Conference (2019) (11)
- Preoperative gemcitabine (gem) and bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma (2008) (10)
- Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704 (2018) (10)
- Stage IV Colorectal Cancer (2003) (10)
- Biologic mesh spacer placement facilitates safe delivery of dose-intense radiation therapy: A novel treatment option for unresectable liver tumors. (2016) (10)
- Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704. (2019) (10)
- Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer (2016) (10)
- Neoadjuvant chemotherapy improves outcomes of chemoradiation therapy for locally advanced pancreatic cancer. (2006) (9)
- Preoperative and adjuvant treatment of localized rectal cancer (2006) (9)
- The Initial Report of Local Control on RTOG 0436: A Phase 3 Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Treated Without Surgery (2014) (9)
- Cisplatin (C) based chemoradiation (CXRT) for locally advanced squamous cell carcinoma (SCCA) of the anal canal (AC): A 20-year perspective. (2011) (9)
- The optimization of dose delivery for intraoperative high-dose-rate radiation therapy using curved HAM applicators. (2006) (9)
- Inter- and intrafraction motion assessment and accumulated dose quantification of upper gastrointestinal organs during magnetic resonance-guided ablative radiation therapy of pancreas patients (2022) (9)
- External Beam Radiation Therapy for Liver Metastases. (2021) (9)
- A phase II trial of preoperative chemotherapy and chemoradiotherapy for potentially resectable adenocarcinoma of the stomach (RTOG 99–04) (2005) (9)
- Phase II study of preoperation mFOLFIRINOX and chemoradiation for high-risk resectable and borderline resectable pancreatic adenocarcinoma. (2015) (9)
- Liver and Bile Duct Cancer (2020) (8)
- Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement (2021) (8)
- Surgical Management of Colorectal Cancer (2003) (8)
- NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937) (2022) (8)
- Neoadjuvant Chemoradiation with Capecitabine Versus Infusional 5-fluorouracil (5-FU) for Locally Advanced Rectal Cancer: A Matched Pair Analysis (2005) (7)
- Radiation therapy in operable and locally advanced pancreatic cancer. (2010) (7)
- Multi-institutional Phase II Trial of Induction Cetuximab Gemcitabine and Oxaliplatin, followed by R (2010) (7)
- SU-FF-T-114: Breath Coaching with Visual Feedback for End-Expiratory Gated Radiotherapy (2006) (7)
- Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions. (2015) (7)
- Comparative analysis of volumetric modulated arc therapy versus intensity modulated radiation therapy for radiotherapy of anal carcinoma. (2011) (7)
- Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. (2022) (7)
- IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer (2019) (7)
- Quality of life after intensity-modulated radiation therapy for anal cancer (2015) (6)
- Prospective evaluation of the effect of ionizing radiation on the bladder tumor-associated (BTA) urine test. (1999) (6)
- Improving Long-Term Survival in Patients With Locally Advanced Pancreatic Cancer via the Delivery of Definitive Radiotherapy Doses. (2015) (6)
- Internal respiratory surrogate in multislice 4D CT using a combination of Fourier transform and anatomical features. (2015) (6)
- Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy (2006) (6)
- Adenocarcinoma of the Colon and Rectum (2003) (6)
- Predicting the node negative mesorectum after preoperative chemoradiation (CRT) for locally advanced rectal carcinoma (2003) (6)
- High-dose-rate remote afterloaders for intraoperative radiation therapy. (2007) (6)
- A Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: RTOG PA0411 (2007) (6)
- Is Personalization of Care Coming to Pancreatic Oncology? (2013) (6)
- Intensity-modulated radiation therapy (IMRT): Differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. (2011) (6)
- A phase II study of capecitabine plus oxaliplatin and radiation therpy, XELOX-XRT, in squamous cell carcinoma (SCCA) of the anal canal: A preliminary analysis (2005) (5)
- Will identifying or targeting altered marker expression in response to cytotoxic therapy be of prognostic or therapeutic value? (2003) (5)
- Balancing Fractionation and Advanced Technology in Consideration of Reirradiation. (2020) (5)
- Stereotactic radiotherapy for pancreatic cancer? (2009) (5)
- Impact of varying air cavity on planning dosimetry for rectum patients treated on a 1.5 T hybrid MR‐linac system (2020) (5)
- Genome-wide host methylation profiling of anal and cervical carcinoma (2021) (5)
- Should cisplatin be avoided in the treatment of locally advanced squamous cell carcinoma of the anal canal? (2009) (5)
- NRG Oncology/RTOG 0438: A Phase 1 Trial of Highly Conformal Radiation Therapy for Liver Metastases. (2019) (5)
- E4201: Randomized phase II study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with locally advanced, unresectable, pancreatic cancer (LAPC): Quality-of-life (QOL) analysis. (2016) (5)
- RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704. (2016) (5)
- Updated survival analysis of preoperative gemcitabine (gem) plus bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma. (2012) (5)
- Epidemiologic Risk Factors (2003) (5)
- Type of recurrence is associated with disease-free survival after salvage surgery for locally recurrent rectal cancer (2021) (5)
- Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery (2021) (5)
- Ablative RT Results in Excellent Local Control and Survival in Localized Pancreatic Cancer (2019) (5)
- Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704 (2018) (5)
- Contemporary perspectives on the use of radiation therapy for locally advanced gallbladder cancer. (2019) (5)
- Preoperative and postoperative chemoradiation for locally advanced rectal cancer: sphincter preservation and survival parameters in patients with pathological response to preoperative chemoradiation (2001) (4)
- Ablative radiation therapy for hepatocellular carcinoma is associated with reduced treatment- and tumor-related liver failure and improved survival. (2021) (4)
- A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. (2019) (4)
- Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, ameliorated capecitabine (X) hand & foot syndrome (HFS) & enhanced survival in metastatic colorectal cancer (MCRC). (2004) (4)
- The association of age with acute toxicities in NRG oncology combined modality lower GI cancer trials. (2019) (4)
- Development of a Comprehensive Clinical Radiation Oncology Resident Didactic Curriculum. (2016) (4)
- Challenges in the Study of Adjuvant Chemoradiation After Pancreaticoduodenectomy (2009) (4)
- Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704. (2020) (4)
- A RAND/UCLA Appropriateness Study of the Management of Familial Gastric Cancer (2013) (4)
- Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma. (2013) (4)
- Impact of diabetes and insulin use on prognosis in patients with resected pancreatic cancer: an ancillary analysis of NRG Oncology RTOG 9704. (2020) (4)
- Magnetic Resonance Imaging-Guided Adaptive Radiotherapy for Colorectal Liver Metastases (2021) (4)
- Trials of locoregional therapies inspired by SABR-COMET (2020) (4)
- Total neoadjuvant therapy for locally advanced rectal cancer. (2017) (4)
- RhuMab VEGF (bevacizumab) with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer: An active, well tolerated regimen (2004) (4)
- Factors Associated With Premature Ovarian Insufficiency in Young Women With Locally Advanced Rectal Cancer Treated With Pelvic Radiation Therapy (2021) (3)
- Chronomodulated infusional 5-FU chemoradiation: Evidence for reduced acute toxicity (1998) (3)
- Role of definitive radiation therapy in carcinoma of unknown primary in the abdomen and pelvis. (2012) (3)
- Preoperative (Neoadjuvant) Therapy for Resectable Adenocarcinoma of the Pancreas (2002) (3)
- Chapter 48 – Pancreatic Cancer (2016) (3)
- Absolute Lymphocyte Count Nadir During Chemoradiation as a Prognostic Indicator of Esophageal Cancer Survival Outcomes (2016) (3)
- Efficacy Outcomes from RTOG 0822: A Phase II Study of Neoadjuvant IMRT with Capecitabine (c) and Oxaliplatin (o) in Patients with Locally Advanced Rectal Cancer (2014) (3)
- Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients with Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase I Trial and Imaging-based Biomarker Validation. (2022) (3)
- Outcomes of Patients With Hepatocellular Carcinoma and Advanced Cirrhosis After High-Dose Radiation Therapy Guided by Functional Liver Imaging With Tc99m Sulfur Colloid Liver SPECT-CT (2016) (3)
- Comparison of Locoregional versus Extended Locoregional Radiation Volumes for Patients with Nonmetastatic Gastro-esophageal Junction Carcinomas (2015) (3)
- Challenges in Reirradiation of Intrahepatic Tumors. (2020) (3)
- Predictors of radiotherapy-related gastrointestinal toxicity from anal cancer DP-IMRT: Secondary analysis of RTOG 0529. (2014) (3)
- Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. (2007) (3)
- Proton Therapy Outcomes for Localized, Unresectable Hepatocellular Carcinoma (2016) (3)
- Phase II study of capecitabine and radiotherapy (RT) plus concomitant boost in patients (pts) with locally advanced rectal cancer (LARC) (2004) (3)
- Conformal Radiation Therapy in Pancreatic Cancer (2002) (3)
- Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. (2017) (3)
- Hypofractionated ablative radiation therapy for hepatocellular carcinoma: practical considerations and review of the literature (2018) (3)
- Interim results of preoperative gemcitabine (gem) plus cisplatin followed by rapid fractionation chemoradiation for resectable pancreatic adenocarcinoma. (2006) (3)
- Staging, prognostic factors, and therapy of localized rectal cancer (2009) (3)
- 5-FU-based adjuvant chemotherapy given after neoadjuvant chemoradiation and surgery for rectal cancer improves survival only among responders (2001) (3)
- A Dynamic Clinical Calculator for Estimating Conditional Recurrence-Free Survival After Total Neoadjuvant Therapy for Rectal Cancer and Either Surgery or Watch-and-Wait Management (2022) (2)
- Preoperative UFT and calcium folinate and radiotherapy in rectal cancer. (1999) (2)
- Multi-institutional phase II study of high dose, hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long term outcomes in patients (pts) with intrahepatic cholangiocarcinoma (ICC). (2015) (2)
- Comparison of pathologic response among three pre-operative chemoradiation regimens for resectable, locally advanced stomach cancer (2000) (2)
- The addition of continuous infusion 5-FU to preoperative radiotherapy increases sphincter preservation in locally advanced low rectal cancer (2001) (2)
- Use of DPC-4 immunostaining of diagnostic cytology specimens to predict the pattern of tumor progression in locally advanced pancreatic cancer patients (LAPC). (2011) (2)
- Neoadjuvant chemoradiation versus surgery first for resectable pancreatic head adenocarcinoma: An economic and outcome analysis. (2012) (2)
- Prospective and Concurrent Analysis of Postresection CA19-9 Level and Surgical Margin Status (SMS) as Predictors of Pattern of Disease Recurrence Following Adjuvant Treatment for Pancreatic Carcinoma: NRG Oncology/RTOG 9704 Secondary Analysis (2015) (2)
- Mismatch repair deficient rectal cancer is resistant to induction combination chemotherapy. (2018) (2)
- Paraneoplastic Thrombocytosis Is a Significant Independent Prognostic Factor for Overall and Progression Free Survival in Locally Advanced Pancreatic Cancer (2014) (2)
- Incidence and Dosimetric Predictors of Radiation-Induced Gastric Bleeding After Chemoradiation for Esophageal and Gastroesophageal Junction Cancer (2021) (2)
- Hypofractionated Radiation Therapy With BED >100 Gy May Rival Surgical Outcomes. (2017) (2)
- Neoadjuvant treatment response and outcomes in locally advanced rectal cancer: Establishing oncologic benchmarks. (2011) (2)
- The Promises and Potential Pitfalls of Organ Preservation for Locally Advanced Rectal Cancer (2006) (2)
- Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal (2006) (2)
- Effective management of treatment-related enteritis during preoperative chemoradiation for locally advanced rectal cancer (2000) (2)
- Survival and Patterns of Failure in Oligometastatic Esophagogastric Cancer (2020) (2)
- Pattern of Spread (2003) (2)
- Recurrence After Resection of Pancreatic Ductal Adenocarcinoma. (2020) (2)
- Erratum: Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy (Abdominal Imaging (2006) 31 (568-574) DOI: 10.1007/s00261-005-0194-y) (2014) (2)
- Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system (2022) (2)
- WITHDRAWN: Biologic mesh spacer placement facilitates safe delivery of dose-intense radiation therapy: A novel treatment option for unresectable liver tumors (2016) (2)
- Phase I trial of radiotherapy with concurrent bevacizumab, erlotinib, and capecitabine for locally advanced pancreatic cancer (LAPC). (2012) (2)
- WR-2721 Reduces Intestinal Toxicity from Concurrent Gemcitabine and Radiation Treatment. (2001) (2)
- The Significance of p16 and p53 Expression on Clinical Outcome in Patients with Anal Cancer Treated with Chemoradiation Therapy: An Analysis of RTOG 98-11 (2014) (2)
- O-10 Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010 (2020) (2)
- Proton Therapy in the Management of Hepatocellular Carcinoma (2022) (2)
- Phase II study of capecitabine and radiotherapy (RT) plus concomitant boost in patients (pts) with locally advanced rectal cancer (LARC). (2004) (2)
- Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy for anal cancer: A large single-institution experience. (2012) (2)
- In response to Li et al.: Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. IJROBP 2003;57:98-104. (2004) (2)
- Radiation Therapy of Resectable Rectal Cancer (2002) (1)
- Proximal Gastric Cancer (2003) (1)
- SU‐FF‐J‐82: Improving Soft Tissue Contrast in 4D CT Images of Liver Cancer Patients Using Deformable Image Registration Method (2006) (1)
- Chemo-Re-Irradiation and Salvage Surgery for Locally Recurrent Rectal Cancer (2021) (1)
- Lack of validation of lymphopenia as a prognostic factor in esophageal cancer chemoradiation (2018) (1)
- In Defense of TNT: A Dynamite Strategy. (2021) (1)
- Gastrointestinal cancer committee (2001) (1)
- Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer (2022) (1)
- Comparative Analysis of Volumetric Modulated Arc Therapy (VMAT) vs. Intensity Modulated Radiation Th (2010) (1)
- Impact of Induction Chemotherapy and Preoperative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction (2006) (1)
- Interobserver Variability in Target Definition for Hepatocellular Carcinoma (HCC) With and Without Portal Vein Thrombus: Radiation Therapy Oncology Group (RTOG) HCC Consensus Panel (2013) (1)
- Characterization of unresectable cholangiocarcinoma patients treated with or without chemoradiation. (2015) (1)
- 4D and multi-phase breath-hold CT imaging with synchronized intravenous contrast injection for liver tumor delineation (2013) (1)
- SU-FF-T-242: Evaluation of Implantable MOSFET Dosimeters for Conventional and Intraoperative Radiation Therapy (2005) (1)
- Impact of preoperative radiation dose escalation on pathologic outcomes and radiation toxicity in locally advanced rectal cancer (LARC): A matched-pair analysis. (2011) (1)
- Erratum to: Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy (2011) (1)
- Effect of dose-escalation of IMRT for unresectable pancreatic cancer 1 cm away from the luminal mucosa on long-term survival. (2015) (1)
- Stereotactic Body Radiotherapy with Functional Treatment Planning in Hepatocellular Carcinoma (2017) (1)
- Predictors of Radiotherapy-related GI Toxicity from Anal Cancer DP-IMRT: Secondary Analysis of NRG Oncology RTOG 0529 (2017) (1)
- Irradiation of recurrent respiratory papillomatosis causing spinal cord compression. (1999) (1)
- Clinical Evaluation of Automatic Organ Contour Propagation Using 4DMRI Images (2017) (1)
- Clinical and pathologic predictors of locoregional recurrence (LR), distant metastasis (DM) and overall survival (OS) in patients treated with chemoradiation and mesorectal excision for locally advanced rectal cancer (2005) (1)
- SU-FF-T-386: Respiratory Gating in the Treatment of Liver Tumors (2006) (1)
- CA19-9 and surgical margin status (SMS) associations with local-regional (LRF) and distant failure (DF) in patients (Pts) with pancreatic cancer: RTOG 9704 secondary analysis. (2015) (1)
- Is There a Role for Intraoperative Radiation Therapy in Patients with Resected Pancreatic Adenocarcinoma? (2009) (1)
- Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma? (2009) (1)
- Intraoperative Radiation Therapy for Locally Advanced Primary and Recurrent Colorectal Cancer: Ten-year Institutional Experience (2012) (1)
- Novel Chemoradiation in Localized Pancreatic Cancer: Clinical Studies (2006) (1)
- Role of surveillance CT scans in resected PC: Correlation with CA19-9 and symptoms. (2010) (1)
- Survival Outcomes for Adjuvant Radiation Therapy Versus no Radiation Therapy in Extrahepatic Cholangiocarcinoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis (2007) (1)
- Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. (2001) (1)
- Circulating tumor DNA (ctDNA) for response assessment in patients with anal cancer treated with definitive chemoradiation. (2023) (1)
- Evolving Concepts Regarding Radiation Therapy for Pancreatic Cancer. (2021) (1)
- Reducing the Morbidity of Rectal Cancer Treatment. (2019) (1)
- Circulating Lymphocyte Count During Neoadjuvant Chemoradiation Therapy for Esophageal Cancer as a Predictive Biomarker of Pathologic Complete Response. (2016) (1)
- Long-term Quality of Life after Chemoradiation for Anal Cancer (2008) (1)
- Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long-course chemoradiation versus short-course radiation therapy. (2023) (1)
- Risk Factors for Gastrointestinal Bleeding in Patients Treated with Radiation Therapy for Intrahepatic Cholangiocarcinoma (2011) (1)
- A phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer (2022) (1)
- Association of human papillomavirus with unique clinicopathologic features in patients with metastatic squamous cell carcinoma of the anal canal. (2014) (1)
- Utility of the of the M. D. Anderson Symptom Assessment Inventory (MDASI) for symptom evaluation during chemoradiation (CRT) in patients with gastrointestinal malignancies (2007) (1)
- Predictors of Radiotherapy-Related GI Toxicity from Anal Cancer DP-IMRT: Secondary Analysis of RTOG 0529 (2014) (1)
- Nonoperative Management of Rectal Cancer Shows Cost-Effectiveness, but Can Comparative Effectiveness Be Established? (2020) (1)
- Radiation for Anorectal Cancers in Patients With a History of Prostate Radiation Therapy. (2021) (1)
- Phase I Trial of Preoperative Radiation Therapy with Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Adenocarcinoma (2011) (1)
- Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal adenocarcinoma: A phase I trial. (2012) (1)
- Potential benefits of integration of therapies with chemoradiation in rectal cancer. (2007) (1)
- Evolution in multimodality management of locally advanced rectal cancer. (2017) (1)
- Stereotactic Ablative Radiation Therapy: Role in Treatment of Liver Metastases (2012) (1)
- Duodenal Dose Sparing With Varying Stomach Volume During IG-IMRT Treatment (2013) (0)
- Preliminary Clinical Experience from a Phase I Feasibility Study of a Novel Permanent Unidirectional Intraoperative Brachytherapy Device (2017) (0)
- Impact of Air Cavity on Planning Dosimetry for Rectum Patients Treated on a 1.5T MR-Linac (2020) (0)
- Phase I S tudy o f P reoperative O ral U racil a nd T egafur Plus L eucovorin a nd R adiation T herapy i n R ectal C ancer (2000) (0)
- Molecular Biology of Gastric Cancer (Table 99-3) (2003) (0)
- Do Socio-Demographic Factors Affect Overall Survival in Patients With Unresectable Pancreatic Cancer?: Results of a Secondary Analysis of RTOG Data (2013) (0)
- Patterns of failure and outcomes in anal adenocarcinoma. (2006) (0)
- The Significance of Coexpression of Epidermal Growth Factor Receptor (EGFR) and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiation Therapy: An Analysis of RTOG 98-11 (2012) (0)
- SU‐E‐J‐33: Comparison Between Soft Tissue Alignment and Bony Alignment for Pancreatic Cancer Radiotherapy (2015) (0)
- Response to Preoperative Chemoradiation Increases the Use of Sphincter Preserving Surgery in Locally Advanced Low Rectal Cancer: 9:00 AM (11) (2002) (0)
- Outcomes Following Hyperfractionated Accelerated Reirradiation for Recurrent Anal Cancer (2016) (0)
- Ablative Radiation Therapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma (2015) (0)
- Is It Safe to Treat the Stomach to ≥50Gy in Esophageal and GE Junction Cancer? (2019) (0)
- Intraoperative Radiation for Pancreatic Cancer (2002) (0)
- Patterns of Locoregional Recurrence and Their Predictors in Rectal Cancer Patients Treated with Surgery and Chemoradiation (2005) (0)
- How Can the Integration of Targeted Agents With Chemoradiation Help Rectal Cancer Patients (2006) (0)
- Number of lymph nodes examined and prognosis among pathologically node-negative patients after preoperative chemoradiation for rectal cancer. (2010) (0)
- Total neoadjuvant chemotherapy to facilitate delivery and tolerance of systemic chemotherapy and response in locally advanced rectal cancer. (2017) (0)
- Abstract 3553: Elevated expression of mismatch repair enzyme MLH1 is associated with prolonged overall survival in resected pancreatic cancer treated with adjuvant chemoradiation, a biomarker analysis of RTOG 9704. (2013) (0)
- Definitive Intent Locoregional IMRT In Oligometastatic Anal Squamous Cell Carcinoma (2020) (0)
- 2109 : Patterns of Locoregional Recurrence in Gastric Cancer Patients Treated With Preoperative Chemoradiation (2006) (0)
- Commentary (Krishnan/Crane): Radiation Therapy in the Treatment of Cholangiocarcinoma (2006) (0)
- 418 Evolution of Outcomes of Patients With Pancreatic Ductal Adenocarcinoma Undergoing Pancreatoduodenectomy Following Preoperative Therapy (2016) (0)
- SU‐GG‐T‐72: A New Technique to Prevent Target Underdosage in Anal Cancer IMRT (2008) (0)
- Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. (2008) (0)
- Functional liver volume from Tc99m sulfur colloid liver SPECT-CT correlates with outcomes of image-guided radiotherapy of liver in patients with cirrhosis (2016) (0)
- Is CA19-9 Response Following Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer an Early Surrogate for Eventual Survival Outcomes? (2013) (0)
- Predictors of Premature Ovarian Failure (POF) in Young Women with Locally Advanced Rectal Cancer (LARC) Treated with Pelvic Radiation Therapy (RT) (2020) (0)
- Ablative Radiation Provides Comparable 1-year Survival to Surgery after Neoadjuvant Chemotherapy for Locally Advanced Pancreatic Adenocarcinoma (2021) (0)
- 1067 : Predictors of Tumor Response and Downstaging in Patients Treated with Preoperative Chemoradiation for Rectal Cancer (2006) (0)
- Salvage ablative radiation therapy for loco-regionally recurrent pancreatic ductal adenocarcinoma following surgical resection. (2022) (0)
- Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials (2023) (0)
- Hyperfractionated Accelerated Reirradiation for Rectal Cancer: A Large Single-Institution Retrospective Analysis (2016) (0)
- Chemoradiotherapy for gastrointestinal cancers (2005) (0)
- Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results (2019) (0)
- SU‐GG‐T‐483: Practical Guidelines for Radiation Treatment Planning and Dose Constraints for Gastro‐Intestinal Cancers (2008) (0)
- Cancer Pain: Palliative radiotherapy (2003) (0)
- Feasibility of Ablative SBRT Treatment of Pancreas Patients on an MR-Linac. (2021) (0)
- Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848. (2021) (0)
- Molecular Markers for Prognosis (2003) (0)
- SU‐GG‐T‐585: The Impact of Free Breathing versus Average 4D CT Image Data on External Beam Radiotherapy Planning for Liver Tumors (2010) (0)
- 980 Preliminary results of a phase I study of rhumab VEGF (bevacizumab) with concurrent radiotherapy (XRT) and capecitabine (CAP) in locally advanced pancreatic cancer (2003) (0)
- In response to Drs. Watanabe and Nagawa (2004) (0)
- Outcomes and patterns of failures after hypofractionated radiation therapy for intrahepatic cholangiocarcinoma. (2019) (0)
- Multi-Institutional Comparison of Ablative Radiation Therapy in 5 Versus 15-25 Fractions for Locally Advanced Pancreatic Cancer (2022) (0)
- Quality of Life After Intensity Modulated Radiation Therapy (IMRT) for Anal Cancer (2013) (0)
- Palliative Therapy for Advanced Disease (2003) (0)
- Predictors of Outcome for Anal Cancer (2010) (0)
- Poster ViewingTargeting Multiple Liver Segments, Including the Entire Right Lobe, With Ablative Radiation Therapy as Salvage Therapy for Patients With Colorectal Liver Metastases Not Eligible for Two-Stage Hepatectomy (2017) (0)
- Feasibility of Organ Preservation With Short Course Radiation Therapy as Part of Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer During the COVID-19 Pandemic (2021) (0)
- PROTON THERAPY: IMPROVEMENT IN CLINICALLY RELEVANT DOSES TO SMALL BOWEL IN RECTAL CARCINOMA (2008) (0)
- The Czito/Anscher/Willet article reviewed (2006) (0)
- In Response to Chien et al. (2009) (0)
- Baseline and temporal patterns of fatigue predict pathological response in patients treated with preoperative chemoradiation therapy (CRT) for rectal cancer (2007) (0)
- CT-Guided Interstitial Low Dose-RATE Brachytherapy for Recurrent Colorectal Cancer. (2021) (0)
- Impact of radiotherapy duration on outcomes in patients with esophageal cancer treated with definitive concurrent radiotherapy and chemotherapy on RTOG trials 8501 and 9405. (2015) (0)
- Visual analog scale (VAS) and time trade-off (TTO) preferences for side effects (SE) of chemoradiation (chemoXRT): A comparison of patients (pts) and caregivers (CG). (2010) (0)
- Role of Radiation Therapy in Hepatocellular Carcinoma (2018) (0)
- In reply [15] (2005) (0)
- Neoadjuvant Treatment of Pancreatic Cancer: Borderline-Resectable Disease (2009) (0)
- Chapter 24 – The Colon and Rectum (2010) (0)
- Oncologic and functional hazards of obesity among patients with locally advanced rectal cancer. (2011) (0)
- Do We Need Intensity-Modulated Radiation Therapy (IMRT) Routinely in the Preoperative Setting for Rectal Cancer? (2012) (0)
- A Computed Tomography Imaging Feature of Pancreatic Cancer As a Predictive Biomarker for Escalated Dose Radiation Therapy (2016) (0)
- Evaluating associations of diabetes, insulin use, and BMI with efficacy in patients with resected pancreatic cancer: An ancillary analysis of NRG Oncology/RTOG 9704. (2017) (0)
- Staging and Therapeutic Approaches for Patients with Localized, Potentially Curable Pancreatic Adenocarcinoma (2005) (0)
- Neoadjuvant versus upfront surgical strategies in patients with resectable pancreatic adenocarcinoma: A decision analysis. (2010) (0)
- (S022) Can Imaging-Based Biomarkers of Pancreatic Cancer be Used to Select Patients for Dose-Escalated Radiotherapy? (2017) (0)
- Multimodal salvage therapy for locally recurrent and re-recurrent rectal cancer. (2010) (0)
- Utility of Tumor Interface Stability as an Imaging Biomarker of Treatment Outcomes in Patients With Pancreatic Cancer Treated With Concurrent Bevacizumab and Radiation Therapy (2017) (0)
- Chemoradiotherapy for Gastric Cancer (2003) (0)
- Novel Approaches in Chemoradiation for Localized Pancreas Cancer (2008) (0)
- Radiotherapy of pancreatic cancer Dose escalation with proton or photon radiation treatment for pancreatic cancer q (2009) (0)
- Use of operability classifications to predict outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. (2012) (0)
- Dose Escalation With an Intensity Modulated Radiation Therapy Technique in 15 to 28 Fractions Is Better Tolerated Than Are Standard Doses of 3DCRT for LAPC (2016) (0)
- Is the presence of acellular mucin in rectal cancer patients with a pathologic complete response to preoperative chemoradiation of prognostic significance (2008) (0)
- Obstruction/Dysphagia/ Early Satiety (2003) (0)
- Is CA19-9 response following induction and consolidation therapy in locally advanced pancreatic cancer (LAPC) an early surrogate marker for eventual survival outcomes? (2015) (0)
- Pursuit of the Abscopal Effect (2020) (0)
- TH‐C‐350‐07: Impacts of Dose Distribution Variations in Proton Therapy According to Gastro‐Intestinal Tract Air Filling and Breathing (2008) (0)
- 56 Results of preoperative radiation and UFT, an oral fluorinated pyrimidine, plus leucovorin in locally advanced rectal cancer—A pilot study (1999) (0)
- Patient preferences for chemoradiation-related side effects. (2009) (0)
- Radiation Therapy Oncology Group (RTOG) trial 0012 of neoadjuvant chemoradiation for distal rectal cancer: Impact on future studies (2006) (0)
- Carcinoma of the Stomach (2017) (0)
- Colorectal Cancer Screening and Risk Factors for Colorectal Cancer (2003) (0)
- Pathologic and Clinical Staging (2003) (0)
- Planned neck dissection as an adjunct to the management of patients with advanced neck disease treated with defintive radiotherapy (1998) (0)
- Erratum: Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation (International Journal of Radiation Oncology Biology) 39:3 (681-686)) (1998) (0)
- Chapter 39 – Palliative Care (2010) (0)
- Genetic Determinants of Chemoradiation Response and Survival in Locally Advanced Esophageal Carcinoma Treated with Trimodality Therapy (2019) (0)
- Methylomic classifiers of anal cancer outcomes: An NRG Oncology / RTOG 98-11 tissue study. (2017) (0)
- Predicting the Achievable Ablative Radiation Dose Coverage to Gross Tumor Volumes in Pancreatic Cancer Patients (2022) (0)
- TU-D-T-617-06: The Optimization of Dose Delivery for Intraoperative High-Dose-Rate Radiation Therapy Using Curved HAM Applicators (2005) (0)
- Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials (2022) (0)
- Ablative Radiation Therapy (RT) Doses in Hepatocellular Carcinoma (HCC): Impact on Local Control, Survival, and Tumor-related Liver Failure (2020) (0)
- Phase I Dose Escalation Trial Using 3-Fraction SBRT for Locally Advanced Pancreatic Cancer. (2021) (0)
- Immune Profile-to-Lymphocyte Ratios During Chemoradiation are Predictors of Clinical Outcomes in Esophageal Cancer (2016) (0)
- EP-1901: Patient-specific deformable image registration quality assurance based on feature points (2016) (0)
- Radiation therapy for de novo anorectal cancer in patients with a history of prostate radiation therapy (2022) (0)
- Dose-escalated external beam radiotherapy in unresectable hepatocellular carcinoma. (2011) (0)
- Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. (2023) (0)
- O-0005RTOG 0436: A PHASE III TRIAL OF CISPLATIN, PACLITAXEL AND RADIATION WITH OR WITHOUT CETUXIMAB IN THE NONOPERATIVE TREATMENT OF ESOPHAGEAL CANCER (2014) (0)
- 218 A Randomized Phase II Study of Gemcitabine 1000mg/msq and Concurrent Radiotherapy Comparing Gemcitabine Alone for Unresectable Locally Advanced Pancreatic Adenocarcinoma (2010) (0)
- HCC: We Prefer Fractionation Versus Dose Reduction. (2023) (0)
- Proton Therapy in the Management of Luminal Gastrointestinal Cancers: Esophagus, Stomach, and Anorectum (2022) (0)
- Adjuvant Treatment of Colon Cancer (2003) (0)
- Chapter 23 – The Liver and Biliary System (2010) (0)
- SU-E-J-157: Comparison Between Internal Respiratory Signal and External Respiratory Signal in 4D CT (2015) (0)
- Benign and Malignant Gallbladder Tumors (2007) (0)
- Principles of radiation oncology (2018) (0)
- TH-E-17A-01: Internal Respiratory Surrogate for 4D CT Using Fourier Transform and Anatomical Features. (2014) (0)
- Quantitative European Association for the Study of the Liver (qEASL) as an Early Biomarker of Response After Radiation Therapy for Intrahepatic Cholangiocarcinoma (2016) (0)
- Dose Escalation with Proton or Photon Radiation Treatment for Pancreatic Cancer (2008) (0)
- Change in Platelet Count and Normal Liver Dosimetry in Patients Receiving Proton Radiation Therapy for Unresectable Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma (2016) (0)
- P a i n a nd Q uality o f L ife A fter T reatment i n P atients W ith Locally R ecurrent R ectal C ancer (2002) (0)
- The rate and risk of secondary pelvic malignancies (SPM) in patients treated with definitive radiation for locally advanced rectal cancer. (2021) (0)
- Phase II trial of maximal ablative irradiation because of encasement (MAIBE) for patients with potentially resectable locally advanced pancreatic cancer. (2023) (0)
- Therapy of Locoregional Disease (2003) (0)
- Abstract IA27: Clinical trials in locally advanced pancreatic cancer (LAPC) (2015) (0)
- Comparison of patterns of failure between T3 and T4 rectal cancer after preoperative chemoradiation (2000) (0)
- 1076 : Does the Addition of Bevacizumab to Chemoradiation Prolong Median Survival In Locally Advanced Pancreatic Cancer Patients? (2006) (0)
- Gynecologic versus gastrointestinal patients: Preferences (prefs) over time for chemoradiation (chemoXRT) side effects (SE) using visual analog scale (VAS) and time trade-off (TTO). (2010) (0)
- Genetic Pathways in Colorectal Cancer (2003) (0)
- Effect of ablative radiotherapy on survival in patients with inoperable intrahepatic cholangiocarcinoma: A dose response analysis. (2016) (0)
- Initial Results of the First Clinical Trial of a Novel Unidirectional Permanent Device for Intraoperative Brachytherapy (2019) (0)
- Definitive liver radiotherapy for intrahepatic cholangiocarcinoma with extrahepatic metastases (2023) (0)
- 19.8. Gallbladder Carcinoma (2008) (0)
- Developments in Chemoradiation for Advanced Pancreatic Cancer (2010) (0)
- Single Institution Retrospective Analysis Of Local Control And Survival Outcomes Using Radiation For The Management Of Colorectal Cancer Liver Metastases (2020) (0)
- SU‐GG‐J‐95: Reproducibility of a Vaginal Dilator Used for Female Anal Cancer Patients (2010) (0)
- Is Marital/Partner Status Associated With Survival in Patients With Resectable Pancreatic Cancer Treated With Adjuvant Postoperative Multi-Modality Therapy?: Results of Secondary Analysis of RTOG 9704 (2014) (0)
- Potential Benefits of Integration of Targeted Therapies With Chemoradiation in Rectal Cancer (2009) (0)
- Reply to another solution that enables ablative radiotherapy for large liver tumors: Percutaneous interstitial high‐dose rate brachytherapy (2016) (0)
- Anal Cancer: Background and Clinical Evidence (2017) (0)
- Preoperative therapy for patients with resectable adenocarcinoma of the pancreatic head (2009) (0)
- Long-Term Results of a Multi-Institutional Phase II Study of Hypofractionated Proton Beam Irradiation of Unresectable Primary Liver Tumors (2022) (0)
- Abstract B36: Maintenance chemotherapy after chemoradiation in patients with locally advanced pancreatic cancer (2019) (0)
- Incidence and Predictors of Chest Wall Toxicity After High Dose Radiation Therapy in 15 Fractions (2015) (0)
- Anal Cancer: Radiation Therapy Planning (2017) (0)
- FOLFOX-Based Chemoradiation as Non-Operative Management for Esophageal Adenocarcinoma (2022) (0)
- Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer. (2023) (0)
- Assessment of Patient-Reported Outcomes in Patients With Anal Squamous-Cell Cancer Undergoing Combined Modality Therapy (2022) (0)
- Prevalence and temporal patterns of persistence of symptoms in 165 rectal cancer patients receiving preoperative chemoradiation therapy (2007) (0)
- A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC). (2023) (0)
- SU‐FF‐J‐43: Correlation Between External Abdominal and Internal Liver Fiducial Motion in 4D‐CT (2006) (0)
- Treatment options for anal carcinoma (2004) (0)
- Definitive Intensity-Modulated Radiation Therapy For Anal Squamous Cell Carcinoma: Outcomes And Toxicities From A Large Single Institution Experience (2020) (0)
- In reply to Bahl et al. (2014) (0)
- Anal Region (2010) (0)
- Radiation Therapy for High-Grade Neuroendocrine Carcinoma of the Rectum and Anal Canal (2014) (0)
- 2062 Pretreatment PSA predicts for biochemical disease free survival in patients treated with post-prostatectomy external beam irradiation (1996) (0)
- Post-Treatment ANC is Predictive of Poorer Overall Survival and Disease-Free Survival in Esophageal Cancer Patients after Tri-Modality Therapy (2019) (0)
- Commissioning and Clinical Use of the CivaSheet, a Novel Shielded Pd103 Array (2017) (0)
- Association of RecQ1 A159C polymorphism with overall survival of patients with resected pancreatic cancer: A replication study in RTOG 9704. (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Christopher H. Crane?
Christopher H. Crane is affiliated with the following schools:
